Drugs / BPS-314d-MR
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01966302 | Nov 2013 → Jun 2019 | pulmonary arterial hypertension | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BPS-314d-MR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01966302 ↗ |
| Route | Oral | “15-150 mcg po BID,” NCT01966302 ↗ |